



Cube Labs

Cube Labs is a holding company/ venture builder, active in the Life Science field. The business model of Cube-Labs, unique in the national panorama, allows the company to position itself as one of the few Italian companies specializing in innovation models in the Life Science sector.

Cube Labs's focus revolves around its ability to incubate, accelerate and transfer to international markets the intellectual ownership of technologies produced by the elite of Italian scientific research.

Cube-Labs is active in the following markets: biotech-MedTech, pharma (with a focus on rare diseases and oncology), digit-healthcare, CleanTech, nutraceuticals, beauty and anti-aging.

Cube Labs has 20 employees, three international branches, ten strategic partnerships, twelve start-ups in portfolio, twenty international patents (and five exclusive licences).

There are 30 technologies in its portfolio and the portfolio's value is 50 million euros.

LEADER

The key person of Cube-Labs is Dr. Filippo Surace (a master's degree Emmas Sda Bocconi and a master degree Empha at Luiss CarloGuidi Businnes School). Founder and President of Cube-Labs since 2013, he has extensive experience in the healthcare industry. Dr Surace is the head of the Surace group, a leading organization in rehabilitation care in the Puglia region.

Dr. Surace is an Associate Professor at Temple University (USA) and an expert in the healthcare and pharmaceutical market. Speaker at the Silicon Valley and winner of numerous innovation awards (China Awards, Le Fonti Awards, Forbes, Fortune, Millionaire, Milano Finanza, Italy Oggi, Economia su +N).



PORTFOLIO'S STRENGTHS

Adamas Biotech and DTech, spin-off of the Cube Labs portfolio, have collaborated to develop a prophylactic technology to treat Covid-19.

The patented formulation of the biogel-bioactive compound is a medical device for nasal use that forms a bio-adhesive layer that physically protects the airways from pathogens, allergens and other harmful particles. The hydrogel forming component is cross-linked with a second component (calciumchloride) to attach the biogel to the mucosa. The nasal and oral spray versions of the product have been registered as Class I medical devices in Italy, allowing them to be sold throughout the EU.

CONTACTS

LEGAL SEAT: via Giulio Caccini 1
Roma

Email: rome.office@cube-labs.com

OFFICES:

via Mangionello 10/12 Maglie (LE)

Email: lecce.office@cube-labs.com

via Legnone 4 Milano

Email: milan.office@cube-labs.com

cube-labs.com